As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Cancer Center — Clinical Trials

 

Head and neck surgeon Kerstin Stenson, MD

Clinical Trial Categories

Bladder Cancers Brain Tumors Breast Cancer
Cancer of Unknown Primary Gastrointestinal Cancers Gynecologic Cancers
Head and Neck Cancers Kidney Cancers Leukemia
Liver Cancers Lung and Chest Tumors Lymphoma
Melanoma and Soft Tissue Cancers Myeloma Pediatric Cancers
Prostate Cancer Sarcomas Spine and Back Cancers
Testicular Cancer    

 

Bladder Cancers

ADAPT Study for Bladder Cancers Not Invading Muscle Tissue
Phase 1/2 study of modern immunotherapy in BCG-relapsing urothelial carcinoma of the bladder.

Treatment Study for Patients With Localized Muscle Invasive Bladder Cancer
Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer.

Treatment Study for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
An open-label, randomized phase 3 study to evaluate enfortumab vedotin vs chemotherapy in subjects with previously treated locally advanced or metastatic urothelial cancer (EV-301).

Urothelial Cancer Treatment Study
A phase 3 study of erdafitinib compared to vinflunine or docetaxel or pembrolizumab in subjects with advanced urothelial cancer and selected FGFR gene aberrations.

Back to top of page

 

Brain Tumors

Genetic Testing in Guiding Treatment for Patients with Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain.

Glioblastoma Drug Treatment Study
A phase II/III randomized trial of veliparib or placebo In combination with adjuvant temozolomide In newly diagnosed glioblastoma with MGMT promoter hypermethylation.

Meningioma Drug Treatment Study
A study looking at targeted therapy according to tumor markers for people with meningiomas.

Patients With Newly Diagnosed Glioblastoma Treatment Study
Randomized phase II trial of hypofractionated dose-escalated photon IMRT or proton beam therapy versus conventional photon irradiation with concomitant and adjuvant temozolomide in patients with newly diagnosed glioblastoma.

Radiation Therapy Study for Patients with IDH Mutant Grade II or III Glioma
A phase II randomized trial of proton vs. photon therapy (IMRT) for cognitive preservation in patients with IDH mutant, low to intermediate grade gliomas.

Treatment Study for Patients with BRAF V600E Mutation Positive Craniopharyngioma
Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas.

Back to top of page

 

Breast Cancer

Medication Trials

Advanced or Metastatic HER2+ Breast Cancer Treatment Study
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for patients with advanced or metastatic HER2+ breast cancer.

Drug Treatment Study for First-Line HER2-Positive Metastatic Breast Cancer
A randomized, double-blind, phase III trial of paclitaxel/trastuzumab/pertuzumab with atezolizumab or placebo in first-line HER2-positive metastatic breast cancer.

Drug Treatment Study for Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer.

HR-Positive HER2-Negative Breast Cancer Treatment Study
A study of multiple immunotherapy-based treatment combinations in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Locally Advanced or Metastatic Triple-Negative Breast Cancer Treatment Study
A phase III, double-blind, placebo-controlled, randomized study of ipatasertib in combination with atezolizumab and paclitaxel as a treatment for patients with locally advanced unresectable or metastatic triple-negative breast cancer.

Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer Treatment Study
A phase II study of neratinib in metastatic HER2 non-amplified but HER2 mutant breast cancer.

Treatment Study for Patients with ER+/HER2- Advanced Breast Cancer
Phase 3 trial of elacestrant vs. standard of care for the treatment of patients with ER+/HER2- advanced breast cancer (EMERALD).

Treatment Study for Patients with HER2-Expressing Cancers
Phase I trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.

Treatment Study for Triple-Negative Breast Cancer or Renal Cell Carcinoma
A phase 2, multi-arm, multicenter, open-label study to evaluate the efficacy and safety of IPI-549 administered in combination with front-line treatment regimens in locally advanced and/or metastatic triple-negative breast cancer or renal cell carcinoma.

Triple-Negative Breast Cancer Drug Treatment Study
Phase III trial to evaluate the efficacy & safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with ≥ 1cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy.

Surgical Trials

Study Assessing the Accuracy of Tumor Biopsies After Chemotherapy
Assessing the accuracy of tumor biopsies after chemotherapy to determine if patients can avoid breast surgery.

Treatment Study for Patients with Node-Positive Breast Cancer
A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.

Treatment Study for Patients with Selected Incurable Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers.

Radiation Trials

Hypofractionated Radiation Therapy After Mastectomy in Patients With Stage IIa-IIIa Breast Cancer
Hypofractionated radiation therapy after mastectomy in preventing recurrence in patients with stage IIa-IIIa breast cancer.

Radiation Therapy Treatment Study for Patients with Early-Stage Breast Cancer
A randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy.

Treatment Study for Patients with Node-Positive Breast Cancer
A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.

Other Breast Cancer Trials

Breast Cancer Microbiome Study
Evaluating the utility of gut and residential environment microbiome as markers of cumulative environmental exposures in breast cancer risk.

Breast Cancer WEight Loss Study (BWEL Study)
A randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.

Diet and Physical Activity Behaviors of Breast Cancer Survivors Study
Diet, activity and lifestyle (DiAL).

Estrogen Receptor Status Study
Determination of estrogen receptor status in patients diagnosed with metastatic breast cancer using cell-free tumor DNA.

Limited Metastatic Breast Cancer Treatment Study
A stage IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.

Back to top of page

 

Cancer of Unknown Primary

Investigational Drug Treatment Study for Patients with Selected Solid Tumors
A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors.

Treatment Study for Patients with Rare Tumors
DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.

Back to top of page

 

Gastrointestinal Cancers

Medication Trials

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.

Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas Treatment Study
Cisplatin, carboplatin and etoposide or temozolomide and capecitabine in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that Is metastatic or cannot Be removed by surgery.

PANOVA-3 Study for Patients with Locally-Advanced Pancreatic Adenocarcinoma
Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma.

Study for Patients with Hepatocellular Carcinoma (HCC)
Phase III, multicenter, randomized, open label study of atezolizumab (anti Pd-L1 antibody) plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma.

Treatment Study for Patients with HER2-Expressing Cancers
Phase I trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.

Treatment Study for Patients with High Risk Stage II-IIIB Anal Cancer
A randomized phase II study of nivolumab after combined modality therapy (CMT) in high risk anal cancer.

Treatment Study for Patients with Selected Incurable Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers.

Treatment Study for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair.

Radiation Trials

Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source
Safety and efficacy of permanently implantable LDR CivaSheet® in combination with external beam radiation in the treatment of pancreatic cancer.

Other Studies

Colonoscopy Research Study
R01 colonoscopy research study.

Polyp Removal Research Study
The goal of the study is to find ways to improve the method by which we remove polyps. We are comparing two different ways – cold snare and jumbo forceps.

Study of Eating Patterns and Alcohol Consumption in Patients with Advanced Tubular Adenoma
Food timing and alcohol study for patients who had advanced tubular adenoma.

Treatment Study for Patients with Colorectal Cancers
A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon or rectal cancer, phase III – preventing adenomas of the colon with eflornithine and sulindac (Paces).

Back to top of page

 

Gynecologic Cancers

Endometrial Cancer Medication Treatment Study
A phase III randomized, placebo-controlled study of pembrolizumab in addition to paclitaxel and carboplatin for measurable stage III or IVA, stage IVB or recurrent endometrial cancer.

Treatment Study for Patients with Cervical or Vaginal Cancer
A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer.

Treatment Study for Patients with Ovarian Cancer
ATHENA: A multicenter, randomized, double-blind, placebo-controlled phase 3 study in ovarian cancer patients evaluating rucaparib and nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy.

Treatment Study for Patients with Recurrent, Refractory, or Metastatic Endometrial Cancer
A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.

Treatment Study for Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Metformin hydrochloride and combination chemotherapy in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.

Treatment Study for Recurrent Platinum-Resistant Ovarian Cancer
The OVAL study: A randomized, controlled, double-arm, double blind, multi-center study of ofranergene obadenovec (VB-111) combined with paclitaxel vs. paclitaxel combined with placebo for the treatment of recurrent platinum-resistant ovarian cancer.

Back to top of page

 

Head and Neck Cancers

Head and Neck Cancer Treatment Study
An open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck.

Oropharyngeal Cancer Treatment Study
A randomized phase II/III trial of de-intensified radiation therapy for patients with early-stage, P16-positive, non-smoking associated oropharyngeal cancer.

The PATHWay Study for Patients with Head and Neck Cancers
The PATHWay study: A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease.

Treatment Study for Patients with Cetuximab-Resistant Advanced Head and Neck Cancer
Phase II HNSCC study using CDX-3379 in combination with cetuximab in patients with cetuximab-resistant advanced HNSCC.

Treatment Study for Patients with Head and Neck Squamous Cell Carcinoma
A phase 2, multi-center, open label study to evaluate efficacy and safety of adenoviral p53 (Ad-p53) in combination with immune checkpoint inhibitor therapy in patients with progression or recurrence of head and neck squamous cell carcinoma (HNSCC).

Treatment Study for Patients with Human Papilloma Virus Associated Head and Neck Squamous Cancer
A phase 1b/2a, multi-center open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic HPV-associated head and neck squamous cancer.

Treatment Study for Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Randomized phase II/III trial of radiotherapy with concurrent MEDI4736 (durvalumab) vs. radiotherapy with concurrent cetuximab in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin.

Treatment Study for Patients with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Cancer
A phase III, randomized, open-label study to evaluate pembrolizumab as neoadjuvant therapy and in combination with standard of care as adjuvant therapy for stage III-IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC).

Back to top of page

 

Kidney Cancers

Combination Treatment Study in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
A randomized, double-blind, controlled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab vs nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate or poor risk.

Renal Cell Carcinoma Treatment Study
Clinical trial with combination therapies in immuno-oncology in advanced renal cell carcinoma.

Treatment Study for Patients with Advanced Renal Cell Carcinoma
A phase II randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in advanced renal cell carcinoma.

Treatment Study for Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
A phase 3 randomized study comparing perioperative nivolumab vs observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

Treatment Study for Patients with Renal Cell Carcinoma
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib or nivolumab and ipilimumab combined with cabozantinib versus sunitinib in participants with previously untreated, advanced or metastatic renal cell carcinoma.

Treatment Study for Renal Cell Carcinoma
An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered intuvax pre-nephrectomy followed by sunitinib post-nephrectomy, compared to sunitinib post-nephrectomy in mRCC.

Back to top of page

 

Leukemia

Childhood B-Lymphoblastic Leukemia Treatment Study
Risk-stratified randomized phase III testing of blinatumomab (IND# I17467, NSC# 765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL).

Chronic Lymphocytic Leukemia in Patients 70 Years of Age and Older Treatment Study
Ibrutinib and obinutuzumab with or without venetoclax in treating older patients with untreated chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia in Younger Patients Treatment Study
Ibrutinib and obinutuzumab with or without venetoclax in treating patients with chronic lymphocytic leukemia.

Clinical Study for Acute Myeloid Leukemia Patients with FLT3 Mutation
Clinical trial with combination therapies in AML with FLT3 mutation in patients not eligible for intensive induction chemotherapy.

FLT3 Mutated Acute Myeloid Leukemia Treatment Study
Phase III randomized study of crenolanib versus midostaurin administered following induction chemotherapy and consolidation therapy in newly diagnosed subjects with FLT3 mutated acute myeloid leukemia.

Myelofibrosis Treatment Study
An open-label, randomized, phase 2 dose-finding study of pacritinib in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis previously treated with ruxolitinib.

Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study
A phase Ill randomized trial investigating bortezomib (NSC #681239; IND #58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy).

Study for Patients with Acute Myelogenous Leukemia
Phase III randomized trial of DFP-10917 vs. non-intensive reinduction (LoDAC, azacitidine, cecitabine) or intensive reinduction (high and intermediate dose cytarabine regimens) for acute myelogenous leukemia patients in second or third salvage.

Study of Transient Myeloproliferative Disorder in Children with Down Syndrome
Biology study of transient myeloproliferative disorder (TMD) in children with Down syndrome (DS).

Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations
A phase III randomized trial for newly diagnosed high risk B-lymphoblastic leukemia (B-ALL) including a stratum evaluating dasatinib (IND#73789, NSC#732517) in patients with Ph-like tyrosine kinase inhibitor (TKI) sensitive mutations.

Treatment Study for Patients with Acute Myeloid Leukemia
A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib (IND# I14480, NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.

Treatment Study for Patients with FLT3/ITD Acute Myeloid Leukemia in First Complete Remission
A phase 3 multi-center, randomized, double-blind, placebo-controlled trial of the FLT3 inhibitor gilteritinib (ASP2215) administered as maintenance therapy following induction/consolidation therapy for subjects with FLT3/ITD AML in 1st complete remission.

Treatment Study for Patients with Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Fedratinib in subjects with intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib.

Treatment Study for Patients with Myelofibrosis
A phase 2 study of INCB050465 in combination with ruxolitinib in subjects with myelofibrosis.

Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma
Treatment of patients with newly diagnosed standard risk B-lymphoblastic leukemia (B-ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy).

Treatment Study for Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-cell ALL.

Vadastuximab Talirine in New Untreated Acute Myeloid Leukemia
Vadastuximab talirine in new untreated AML.

Back to top of page

 

Liver Cancers

Treatment Study for Patients with Advanced Liver Cancer
A randomized, controlled phase 3 study of cabozantinib (XL184) in combination with atezolizumab versus sorafenib in subjects with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy.

Back to top of page

 

Lung and Chest Tumors

Medication Trials

Completely Resected EGFR Mutant Non-Small Cell Lung Cancer Treatment Study
Randomized study of erlotinib vs observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).

Drug Treatment Study for Small Cell Lung Cancer
A phase 3, controlled, open-label, randomized study of RRx-001 administered sequentially with a platinum doublet or a platinum doublet in third-line or beyond small cell lung cancer (SCLC).

Early Stage Unresected Non-Small Cell Lung Cancer Treatment Study
Durvalumab vs placebo following stereotactic body radiation therapy in early stage unresected non-small cell lung cancer patients.

Investigational Drug Treatment Study for Patients with Selected Solid Tumors
A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors.

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Stage IV Non-Small Cell Lung Cancer Study
Maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC): A randomized phase II/III trial.

Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer Study
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer.

Non-Small Cell Lung Cancer Treatment Study
Nivolumab after surgery and chemotherapy in treating patients non-small cell lung cancer.

Stage III (N2) Non-Small Cell Lung Cancer Treatment Study
A phase II study of concurrent chemoradiation plus durvalumab (MEDI4736) followed by surgery followed by adjuvant durvalumab in medically operable patients with surgically resectable stage III (N2) non-small cell lung cancer.

Stages II and III Non-Small Cell Lung Cancer Treatment Study
A phase III, double-blind, placebo controlled, multi-center international study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer.

Study for Patients with Completely Resected Stage IB to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
A phase III, open-label, randomized study to evaluate the efficacy and safety of adjuvant alectinib versus adjuvant platinum-based chemotherapy in patients with completely resected stage IB to stage IIIA anaplastic lymphoma kinase-positive NSCLC.

Study of Advanced Non-Small Cell Lung Cancer that has Progressed on First-Line Osimertinib Therapy
A biomarker-directed phase 2 platform study in patients with advanced non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy.

Study of Immunotherapy Alone or with Chemotherapy as Treatment in Non-Small Cell Lung Cancer
A randomized, phase III study of firstline immunotherapy alone or in combination with chemotherapy in induction/maintenance or postprogression in advanced nonsquamous non‐small cell lung cancer (NSCLC) with immunobiomarker signature‐driven analysis.

Surgically Resected ALK-Positive Early Stage Non-Small Cell Lung Cancer Treatment Study
A randomized phase III trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus observation for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.

Treatment Study for Patients with EGFR Mutation and ALK Positive Non-Small Cell Lung Cancer
Phase II multi-center study of pembrolizumab in combination with platinum-based doublet chemotherapy in patients with EGFR mutation and ALK positive non-small cell lung cancer with progressive disease following prior tyrosine kinase inhibitors (TKIs).

Treatment Study for Patients with Selected Incurable Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers.

Treatment Study for Stage IIIA/IIIB Non-Small Cell Lung Cancer
Phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).

Radiation Trials

Limited Stage Small Cell Lung Cancer Treatment Study
Chemoradiation with or without atezolizumab in treating patients with limited stage small cell lung cancer./p>

The MAVERICK Trial for Small-Cell Lung Cancer
MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation (PCI): A randomized phase III trial in small-cell lung cancer (MAVERICK).

Radiation Therapy Treatment Study for Patients with Limited-Stage Small Cell Lung Cancer
Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide.

Treatment Study for Patients with Stage IV Non-Small Cell Lung Cancer
A randomized two arm phase II trial of pembrolizumab alone or sequentially following single fraction non-ablative radiation to one of the target lesions, in previously treated patients with stage IV NSCLC.

Back to top of page

 

Lymphoma

Assessing the Anti-Tumor Activity and Safety of REGN1979 in Patients with Relapsed or Refractory Follicular Lymphoma
Assessing the anti-tumor activity and safety of REGN1979 in patients with relapsed or refractory follicular lymphoma.

Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study
A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype.

Diffuse Large B-Cell Lymphoma Treatment Study
A phase 2 study of the combination of ublituximab + TGR-1202 and TG-1202 alone in patients with previously treated diffuse large B-cell lymphoma.

Drug Treatment Study for High Grade B-Cell Lymphomas
Randomized phase II/III study of venetoclax (ABT199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double expressing lymphomas.

Drug Treatment Study for Patients with Follicular Lymphoma
Study of ME-401 in subjects with follicular lymphoma after failure of two or more prior therapies.

Follicular Lymphoma Treatment Study
Study of ibrutinib and rituximab in subjects whose follicular lymphoma has not been treated before.

Mantle Cell Lymphoma Treatment Study
A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission.

MYC-Associated B-Cell Lymphomas Treatment Study
Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomas.

Nivolumab and Combination Chemotherapy in Treating Participants with Diffuse Large B-Cell Lymphoma
Nivolumab and combination chemotherapy in treating participants with diffuse large B-cell lymphoma.

Relapsed/Refractory Hodgkin Lymphoma Treatment Study
Brentuximab vedotin and nivolumab with or without ipilimumab to treat relapsed or refractory Hodgkin lymphoma.

Relapsed or Refractory Follicular Lymphoma Treatment Study
Obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy in treating patients with relapsed or refractory follicular lymphoma.

Relapsed or Refractory Mantle Cell Lymphoma Treatment Study
A phase 2, open-label, 2-cohort, multicenter study of INCB050465, a PI3Kδ inhibitor, in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor (CITADEL-205).

Relapsed or Refractory Non-Hodgkin’s B-Cell Lymphoma Treatment Study
Combination gemcitabine and oxaliplatin (GEMOX) therapy with MT-3724 for subjects with relapsed or refractory non-Hodgkin’s B-cell lymphoma.

Treatment Study for the Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma
A double blind, randomized, vehicle controlled, crossover study to evaluate the safety and efficacy of a topical lotion, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

Treatment Study for Patients with Cutaneous T-Cell Lymphoma
A clinical study to demonstrate safety and efficacy of E7777 (denileukin diftitox) in persistent or recurrent cutaneous T-cell lymphoma.

Treatment Study for Patients with Diffuse Large B-Cell Lymphoma After aHCT
Effect of blinatumomab on minimal residual disease in subjects with diffuse large B-cell lymphoma post-autologous hematopoietic stem-cell transplantation.

Treatment Study for Patients with Marginal Zone Lymphoma
Study of acalabrutinib alone or in combination with rituximab in indolent B-cell non-Hodgkin lymphoma.

Treatment Study for Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Immunotherapy (nivolumab or brentuximab vedotin) plus combination chemotherapy in treating patients with newly diagnosed stage III-IV classic Hodgkin lymphoma.

Treatment Study for Patients with Relapsed/Refractory T-Cell Lymphoma
An open label, phase I/II study to evaluate the safety and efficacy of tenalisib (RP6530), a novel PI3K δ/γ dual inhibitor, given in combination with a histone deacetylase inhibitor, romidepsin, in adult patients with relapsed/refractory T-cell lymphoma.

Treatment Study for Patients with Relapsed or Refractory Non-Hodgkin’s B-cell Lymphoma
Multiple dose regimens of MT-3724 with lenalidomide for the treatment of patients with relapsed/refractory diffuse large B-cell (DLBCL) non-Hodgkin’s lymphoma.

Back to top of page

 

Melanoma and Soft Tissue Cancers

Drug Treatment Study with Radiation in Advanced Tumors
A phase I dose-escalating study of RiMO-301 with radiation in advanced tumors.

Treatment Study For Patients With Advanced BRAFV600 Mutant Melanoma
Dabrafenib + trametinib followed by ipilimumab + nivolumab at progression or ipilimumab + nivolumab followed by dabrrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma.

Treatment Study for Patients with Merkel Cell Carcinoma
Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab: A phase III trial.

Treatment Study for Patients with Metastatic Merkel Cell Carcinoma
A phase 2 study of INCMGA00012 in patients with metastatic merkel cell carcinoma.

Treatment Study for Patients with Selected Incurable Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers.

Treatment Study for Patients with Unresectable Stage III or Stage IV Melanoma
Nivolumab plus ipilimumab plus sargramostin versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma.

Back to top of page

 

Myeloma

Cell-Based Therapy Study for Patients with Multiple Myeloma
Descartes-11 in relapsed or refractory multiple myeloma.

Maintenance Study For Patients With Residual Myeloma Post-Transplant
Phase II randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide vs. consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma.

Back to top of page

 

Pediatric Cancers

Hepatoblastoma Treatment Study
Treatment of children with all stages of hepatoblastoma with temsirolimus (IND#122782, NSC#683864) added to high risk stratum treatment.

Newly Diagnosed Classical Hodgkin Lymphoma Treatment Study
A randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.

Treatment Study for Patients with Anaplastic Large Cell Lymphoma
A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117.

Treatment Study of Non-Metastatic Desmoplastic Medulloblastoma in Children
A Phase II study for the treatment of non-metastatic desmoplastic medulloblastoma in children less than 4 years of age.

Back to top of page

 

Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer Treatment Study
A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).

Novel Treatment Combination Study for Metastatic Prostate Cancer Patients
A phase II randomized study of overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of LY2157299 and enzalutamide.

Prostate Cancer Study
Phase 3, double blind trial, using investigational product in asymptomatic subjects with Gleason sum equal to or lesser than 7, metastatic androgen independent prostatic adenocarcinoma.

Radiation Therapy Treatment Study for Stage III-IV Prostate Cancer
A phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer.

SBRT for Localized Prostate Cancer Study
A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.

Study of Combination Therapy for High Risk Prostate Cancer
Niraparib with standard combination radiation therapy and androgen deprivation therapy in treating patients with high risk prostate cancer.

Study of Standard Systemic Therapy in Treating Prostate Cancer
Phase III randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer.

Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer
Phase III trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer (mCRPC).

Treatment Study for Patients with Prostate Cancer
Phase II-III trial of adjuvant radiotherapy following radical prostatectomy with or without adjuvant docetaxel.

Treatment Study for Patients with Prostate Cancer with DNA Repair Defects
A randomized phase II trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.

Treatment Study for Patients with Selected Incurable Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers.

Back to top of page

 

Sarcomas

Ewing Sarcoma Treatment Study
Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab to multi agent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma.

Proton or Photon RT for Retroperitoneal Sarcomas Study
Phase I/II trial of pre-operative image guided intensity modulated proton radiation therapy (IMPT) or photon (IMRT) with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas.

Treatment Study for Patients with Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Pazopanib neoadjuvant trial in non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib.

Treatment Study for Patients With Soft Tissue Sarcoma
A phase Ib trial of neoadjuvant AMG 232 concurrent with preoperative radiotherapy in wild-type P53 soft tissue sarcoma (STS).

Back to top of page

 

Spine and Back Cancers

Registry for the Management and Outcome of Metastatic Spine Tumors
Metastatic Tumor Research and Outcome Network: A multicenter prospective registry for the management and outcome of metastatic spine tumors.

Back to top of page

 

Testicular Cancer

Back to top of page